| 1. |
Chester W. About lipoidgranulomatose. Virchows Arch Pathol Anat, 1930, 279(2): 561-602.
|
| 2. |
Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood, 2020, 135(16): 1311-1318.
|
| 3. |
Cohen-Aubart F, Emile JF, Carrat F, et al. Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort. Am J Hematol, 2018, 93(5): E114-E117.
|
| 4. |
Estrada-Veras JI, O’Brien KJ, Boyd LC, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv, 2017, 1(6): 357-366.
|
| 5. |
Diamond EL, Dagna L, Hyman DM, et al. Consensus Guidelines for the Diagnosis and Clinical Management of Erdheim-Chester Disease. Blood, 2014, 124(4): 483-492.
|
| 6. |
Ghotra AS, Thompson K, Lopez-Mattei J, et al. Cardiovascular manifestations of Erdheim-Chester disease. Echocardiography, 2019, 36(2): 229-236.
|
| 7. |
Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore), 2004, 83(6): 371-392.
|
| 8. |
Pegoraro F, Papo M, Maniscalco V, et al. Erdheim-Chester disease: a rapidly evolving disease model. Leukemia, 2020, 34(11): 2840-2857.
|
| 9. |
Brun AL, Touitou-Gottenberg D, Haroche J, et al. Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol, 2010, 20: 2579-2587.
|
| 10. |
Mirmomen SM, Sirajuddin A, Nikpanah M, et al. Thoracic involvement in Erdheim–Chester disease: computed tomography imaging findings and their association with the BRAFV600E mutation. Eur Radiol, 2018, 28: 4635-4642.
|
| 11. |
Gumeler E, Onur MR, Karaosmanoglu AD, et al. Computed tomography and magnetic resonance imaging of peripelvic and periureteric pathologies. Abdom Radiol (NY), 2018, 43(9): 2400-2411.
|
| 12. |
Manaka K, Sato J, Makita N. Neuroendocrine manifestations of Erdheim-Chester disease. Handb Clin Neurol, 2021, 181: 137-147.
|
| 13. |
Courtillot C, Laugier Robiolle S, Cohen Aubart F, et al. Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester disease. J Clin Endocrinol Metab, 2016, 101(1): 305-313.
|
| 14. |
Haroche J, Cluzel P, Toledano D, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a mono-centric series of 37 patients. Circulation, 2009, 119(25): e597-e598.
|
| 15. |
Julien H, Fleur C, Barret JR, et al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol, 2017, 18(2): e113-e125.
|
| 16. |
Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet, 2006, 367(9506): 241-251.
|
| 17. |
Courcoul A, Vignot E, Chapurlat R. Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine, 2014, 81(2): 175-177.
|
| 18. |
Diamond EL, Abdel-Wahab O, Durham BH, et al. Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. Blood, 2016, 128(14): 1896-1898.
|
| 19. |
Tran TA, Pariente D, Guitton C, et al. Treatment of Erdheim-Chester disease with canakinumab. Rheumatology, 2014, 53(12): 2312-2314.
|
| 20. |
Cohen-Aubart F, Maksud P, Emile JF, et al. Efficacy of infliximab in the treatment of Erdheim-Chester disease. Ann Rheum Dis, 2018, 77(9): 1387-1390.
|
| 21. |
Berti A, Cavalli G, Guglielmi B, et al. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology, 2017, 6(6): e1318237.
|
| 22. |
Gianfreda D, Nicastro M, Galetti M, et al. Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood, 2015, 126(10): 1163-1171.
|
| 23. |
Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Disco, 2016, 6(2): 154-165.
|
| 24. |
Cohen Aubart F, Emile JF, Maksud P, et al. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease. Br J Haematol, 2018, 180(1): 150-153.
|
1/5
WeChat